

William Blalock

Publications:

Journal Articles:

First or corresponding author:

- Piazzini, M., Bavelloni, A., Faenza, I. and **Blalock, W.L.** Glycogen synthase kinase (GSK)-3 and the double-strand RNA-dependent kinase, PKR: when two kinases for the common good turn bad. (2020). *Biochem Biophys Acta Mol Cell Res.* (In press).
- Piazzini, M., Bavelloni, A., Gallo, A., **Blalock, W.L.** AKT-Dependent Phosphorylation of ADAR1p110 and ADAR2 Represents a New and Important Link Between Cell Signaling and RNA Editing. (2020). *DNA Cell Biol.* **39**: 343-348.
- Piazzini, M., Bavelloni, A., Greco, S., Focaccia, E., Orsini, A., Benini, S., Gambarotti, M., Faenza, I. and **Blalock, W.L.** Expression of the double-stranded RNA-dependent kinase PKR influences osteosarcoma attachment independent growth, migration, and invasion. (2020). *J Cell Physiol.* **235**: 1103-1119.
- Piazzini, M., Bavelloni, A., Gallo, A., Faenza, I. and **Blalock, W.L.** Signal Transduction in Ribosome Biogenesis: A Recipe to Avoid Disaster. (2019). *Int J Mol Sci.* **20**: 2718.
- Bavelloni, A., Focaccia, E., Piazzini, M., Raffini, M., Cesarini, V., Tomaselli, S., Orsini, A., Ratti, S., Faenza, I., Cocco, L., Gallo, A. (co-corresponding) and **Blalock, W.L.** (co-corresponding). AKT-dependent phosphorylation of the adenosine deaminases, ADAR-1 and -2 inhibits deaminase activity. (2019). *FASEB J.* **33**: 9044-9061.
- Bavelloni, A., Focaccia, E., Piazzini, M., Orsini, A., Ramazzotti, G., Cocco, L., **Blalock, W.** (co-corresponding) and Faenza, I. (co-corresponding). Therapeutic potential of NVP-BKM120 in human osteosarcoma cells. (2019). *J. Cell. Physiol.* **234**: 10907-10917.
- Bavelloni, A., Ramazzotti, G., Poli, A., Piazzini, M., Focaccia, E., **Blalock, W.** (co-corresponding) and Faenza I (co-corresponding). MiRNA-210: A Current Overview. (2017). *Anticancer Res.* **37**: 6511-6521.
- Bavelloni, A., Focaccia, E., Piazzini, M., Errani, C., **Blalock, W.** (co-corresponding) and Faenza I. (co-corresponding). Cell Cycle Arrest and Apoptosis Induced by Kinamycin F in Human Osteosarcoma Cells. (2017). *Anticancer Res.* **37**: 4103-4109.
- Blalock, W.L.** (co-corresponding), Piazzini, M., Gallo, A., Bavelloni, A., Focaccia, E. and Faenza, I. (co-corresponding). RNA processing and ribosome biogenesis in bone marrow failure disorders. (2017). *RNA & Disease.* **4**: e1531.
- Bavelloni, A., Piazzini, M., Raffini, M., Faenza, I. and **Blalock, W.L.** Prohibitin 2: At a communications crossroads. (2015). *IUBMB Life.* **67**: 239-254.
- Bavelloni, A., Piazzini, M., Faenza, I., Raffini, M., D'Angelo, A., Cattini, L., Cocco, L. and **Blalock, W.L.** Prohibitin 2 represents a novel nuclear AKT substrate during all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. (2014). *FASEB J.* **28**: 2009-2019.
- Blalock, W.L.** (corresponding), Piazzini, M. (co-first author), Bavelloni, A., Raffini, M., Faenza, I., D'Angelo, A. and Cocco, L. Identification of the PKR nuclear interactome reveals roles in ribosome biogenesis, mRNA processing and cell division. (2014). *J. Cell. Physiol.* **229**: 1047-1060.

- Blalock,WL.** and Cocco, L. EIF2AK2 (eukaryotic translation initiation factor 2-alpha kinase2). (2012). *Atlas Genet. Cytogenet. Oncol. Haematol.* **16:** 601-613. (<http://AtlasGeneticsOncology.org/Genes/EIF2AK2ID41866ch2p22.html>)
- Blalock,WL.**, Bavelloni,A., Piazzzi,M., Tagliavini,F., Faenza,I., Martelli,AM., Follo,MY. and Cocco,L. Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress. (2011). *Leukemia* **25:** 236-245.
- Blalock,WL.**, Bavelloni,A., Piazzzi,M., Faenza,I. and Cocco,L. A role for PKR in hematologic malignancies. (2010). *J. Cell. Physiol.* **223:** 572-591.
- Blalock,WL.**, Grimaldi,C., Falà,F., Follo,M., Horn,S., Basecke,J., Martinelli,G., Cocco,L. and Martelli,AM. PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. (2009). *J. Cell. Physiol.* **221:** 232-241.
- Falà,F. (co-1st author), **Blalock,WL. (co-1st author)**, Tazzari,PL., Cappellini,A., Chiarini,F., Martinelli,G., Tafuri,A., McCubrey,JA., Cocco,L. and Martelli,AM. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine (A443654) in T-cell acute lymphoblastic leukemia. (2008). *Mol. Pharmacol.* **74:** 884-895.
- Bennett,RL.(co-1st author), **Blalock,WL. (co-1st author)**, Abtahi,DM., Pan,Y., Moyer,SA. and May,WS. RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy and viral infection. (2006). *Blood* **108:** 821-829.
- Shelton,JG. (co-1st author), **Blalock,WL. (co-1st author)**, White,ER., Steelman,LS. and McCubrey, JA. Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. (2004). *Cell Cycle* **4:** 503-512.
- Blalock,WL.**, Navolanic,PM., Steelman,LS., Shelton,JG., Moye,PW., Lee,JT., Franklin,RA., Mirza,A., McMahan,M., White,MK. and McCubrey,JA. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. (2003). *Leukemia* **17:** 1058-1067.
- Blalock,WL.**, Pearce,M., Chang,F., Lee,JT., Pohnert,SC., Burrows,C., Steelman,LS., Franklin,RA., McMahan,M. and McCubrey,JA. Effects of inducible MEK1 activation on the cytokine dependency of lymphoid cells. (2001). *Leukemia* **15:** 794-807.
- Blalock,WL.**, Moye,P., Chang,F., Pearce,M., Steelman,LS., and McCubrey,JA. Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine-dependency of human and murine hematopoietic cells. (2000). *Leukemia* **14:** 1080-1096.
- Blalock,WL.**, Pearce,M., Steelman,LS., Franklin,R., McCarthy,S., Cherwinski,H., McMahan,M. and McCubrey,JA. A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells. (2000). *Oncogene* **19:** 526-536.
- Blalock,WL.**, Weinstein-Oppenheimer,C., Chang,F., Hoyle,PE., Wang,XY., Algate,PA., Franklin,RA., Oberhaus,SM., Steelman,LS. and McCubrey,JA. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. (1999). *Leukemia* **13:** 1109-1166.

Co-author:

- Giannaccare,G., **Blalock,W.**, Fresina,M., Vagge,A. and Versura,P. Intolerant contact lens wearers exhibit ocular surface impairment despite 3 months wear discontinuation. (2016). *Graefes Arch. Clin. Exp. Ophthalmol.* **254**:1825-1831.
- Ramazzotti,G., Bavelloni,A., **Blalock,W.**, Piazzzi,M., Cocco,L. and Faenza,I. BMP-2 Induced Expression of PLC β 1 That is a Positive Regulator of Osteoblast Differentiation. (2016). *J. Cell. Physiol.* **231**:623-629.
- Piazzzi,M., **Blalock,WL.**, Bavelloni,A., Faenza,I., Raffini,M., Tagliavini,F., Manzoli,L. and Cocco,L. PI-PLC β 1b affects Akt activation, cyclin E expression, and caspase cleavage, promoting cell survival in pro-B-lymphoblastic cells exposed to oxidative stress. (2015). *FASEB J.* **29**:1383-1394.
- Bavelloni,A., Dmitrienko,GI., Goodfellow,VJ., Ghavami,A., Piazzzi,M., **Blalock,W.**, Chiarini,F., Cocco,L. and Faenza,I. PLC β 1a and PLC β 1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation. (2015). *J. Cell. Physiol.* **230**: 587-594.
- Bavelloni,A., Poli,A., Fiume,R., **Blalock,W.**, Matteucci,A., Ramazzotti,G., McCubrey,JA., Cocco,L. and Faenza, I. PLC-beta 1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cells. (2014). *Oncotarget* **5**: 4222-4231.
- Follo,MY., Faenza,I., Piazzzi,M., **Blalock,WL.**, Manzoli,L., McCubrey,JA. and Cocco,L. Nuclear PI-PLC β 1: an appraisal on targets and pathology. (2014). *Adv. Biol. Regul.* **54**: 2-11.
- Piazzzi,M., **Blalock,WL.**, Bavelloni,A., Faenza,I., D'Angelo,A., Maraldi,NM. and Cocco,L. Phosphoinositide-specific phospholipase C β 1b (PI-PLC β 1b) interactome: affinity purification-mass spectrometry analysis of PI-PLC β 1b with nuclear proteins. (2013). *Mol. Cell. Proteomics* **12**: 2220-2235.
- Versura,P., Bavelloni,A., **Blalock,W.**, Fresina,M. and Campos,EC. A rapid standardized quantitative microfluidic system approach for evaluating human tear proteins. (2012). *Mol. Vis.* **18**: 2526-2537.
- Faenza,I., **Blalock,W.**, Bavelloni,A., Shoser,B., Fiume,R., Pacella,S., Piazzzi,M., D'Angelo,A., and Cocco,L. A role for PLC β 1 in myotonic dystrophies type 1 and 2. (2012). *FASEB J.* **26**: 3042-3048.
- Piazzzi,M., Bavelloni,A., Faenza,I., **Blalock,W.**, Urbani,A., D'Aguanno,S., Fiume,R., Ramazzotti,G., Maraldi,NM. and Cocco,L. eEF1A phosphorylation in the nucleus of insulin-stimulated C2C12 myoblasts: Ser⁵³ is a novel substrate for protein kinase C β I. (2010). *Mol. Cell Proteomics* **9**: 2719-2728.
- Versura,P., Nanni,P., Bavelloni,A., **Blalock,WL.**, Piazzzi,M., Roda,A. and Campos,EC. Tear proteomics in evaporative dry eye disease. (2010). *Eye* **24**: 1396-1402.
- Ventura,E., Sassi,F., Fossati,S., Parodi,A., **Blalock,W.**, Balza,E., Castellani,P., Borsi,L., Carnemolla,B. and Zardi,L. Use of uteroglobin for the engineering of polyvalent, polyspecific fusion proteins. (2009). *J. Biol. Chem.* **284**: 26646-26654.
- Balza,E., Sassi,F., Ventura,E., Parodi,A., Fossati,S., **Blalock,W.**, Carnemolla,B., Castellani,P., Zardi,L. and Borsi,L. A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B. (2009). *Intl. J. Cancer* **125**: 751-758.
- Bennett,RL., **Blalock,WL.**, Choi,EJ., Lee,YJ., Zhang,Y., Zhou,L., Oh,SP. and May,WS. RAX is required for fly neuronal development and mouse embryogenesis. (2008). *Mech. Dev.* **125**: 777-785.
- Follo,MY., Finelli,C., Mongiorgi,S., Clissa,C., Bosi,C., Martinelli,G., **Blalock,WL.**, Cocco,L. and Martelli,AM. PKR is activated in MDS patients and its subcellular localization depends on disease severity. (2008). *Leukemia* **22**: 2267-2269.

- Follo,MY., Finelli,C., Bosi,C., Martinelli,G., Mongiorgi,S., Baccarani,M., Manzoli,L., **Blalock,WL.**, Martelli,AM. and Cocco,L. PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. (2008). *Leukemia* **22**: 198-200.
- Martelli,AM., Evangelisti,C., Chiarini,F., **Blalock,WL.**, Papa,V. and Fala,F. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network as a new target for acute myelogenous leukemia therapy. (2007). *Cancer Ther.* **5**: 309-330.
- Martelli,AM., Tazzari,PL., Evangelisti,C., Chiarini,F., **Blalock,WL.**, Billi,AM., Manzoli,L., McCubrey,JA. and Cocco,L. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: From bench to bedside. (2007). *Curr. Med. Chem.* **14**: 2009-2023.
- Bennett,RL., **Blalock,WL.** and May,WS. Serine 18 phosphorylation of RAX, the PKR activator, is required for PKR activation and consequent translation inhibition. (2004). *J. Biol. Chem.* **279**: 42687-42693.
- Shelton, JG., Moye,PW., Steelman,LS., **Blalock,WL.** Lee,JT., Franklin,RA., McMahon,M. and McCubrey,JA. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. (2003). *Leukemia* **17**: 1765-1782.
- Chang,F., Steelman,LS., Lee,JT., Shelton,JG., Navolanic,PM., **Blalock,WL.**, Franklin,RA. and McCubrey,JA. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. (2003). *Leukemia* **17**: 1263-1293.
- Shelton,JG., Steelman,LS., Lee,JT., Knapp,SL., **Blalock,WL.**, Moye,PW., Franklin,RA., Pohnert,SC., Mirza,AM., McMahon,M. and McCubrey,JA. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. (2003). *Oncogene* **22**: 2478-2492.
- Chang,F., Lee,JT., Navolanic,PM., Steelman,LS., Shelton,JG., **Blalock,WL.**, Franklin,RA. and McCubrey,JA. Involvement of PI3K/AKT pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. (2003). *Leukemia* **17**: 590-603.
- Chang,F., Steelman,LS., Shelton,JG., Lee,JT., Navolanic,PM., **Blalock,WL.**, Franklin,R. and McCubrey,JA. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. (2003). *Int. J. Oncol.* **22**: 469-480.
- Saleh,OA., **Blalock,WL.**, Burrows,C., Steelman,LS., Doshi,PD., McKearn,JP. and McCubrey,JA. Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells. (2002). *Int. J. Mol. Med.* **10**: 385-394.
- McCubrey,JA., Lee,JT., Steelman,LS., **Blalock,WL.**, Moye,PW., Chang,F., Pearce,M., Shelton,JG., White,MK., Franklin,RA. and Pohnert,SC. Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. (2001). *Cancer Detect. Prev.* **25**: 375-393.
- McCubrey,JA., **Blalock,WL.**, Saleh,O., Pearce,M., Burrows,C., Steelman,LS., Lee,JT., Franklin,RA., Oberhaus,SM., Moye,PW., Doshi,PD. and McKearn,JP. Enhanced ability of daniplestim and myelopoietin-1 to suppress apoptosis in human hematopoietic cells. (2001). *Leukemia* **15**: 1203-1216.
- McCubrey,JA., Steelman,LS., **Blalock,WL.**, Lee,JT., Moye,PW., Chang,F., Pearce,M., Shelton,JG., White,MK., Franklin,RA. and Pohnert,SC. Synergistic effects of pi3k/akt on abrogation of cytokine-dependency induced by oncogenic raf. (2001). *Adv. Enzyme Regul.* **41**: 289-323.

- Ruvolo,PP., Gao,F., **Blalock,WL.**, Deng,X. and May,WS. Ceramide regulates protein synthesis by novel mechanism involving the cellular PKR activator RAX. (2001). *J. Biol. Chem.* **276**: 11754-11758.
- Weinstein-Oppenheimer,CR., **Blalock,WL.**, Steelman,LS., Chang,F. and McCubrey,JA. The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-dependent tumors. (2000). *Pharmacol. Therapeut.* **88**: 229-279.
- Weinstein-Oppenheimer,CR., Steelman,LS., Algate,PA., **Blalock,WL.**, Burrows,C., Hoyle,PE., Lee,JT., Moye,PW., Shelton,JG., Franklin,RA. and McCubrey,JA. Effects of deregulated Raf activation on integrin, cytokine-receptor expression and the induction of apoptosis in hematopoietic cells. (2000). *Leukemia* **14**: 1921-1938.
- Moye,PW., **Blalock,WL.**, Weinstein-Oppenheimer,CR., Pearce,M., Steelman,LS. and McCubrey,JA. Synergy between Raf and BCL-2 in abrogating the cytokine-dependency of hematopoietic cells. (2000). *Leukemia* **14**: 1060-1079.
- McCubrey,JA., Steelman,LS., Moye,PW., Hoyle,PE., Weinstein-Oppenheimer,C., Chang,F., Pearce,M., White,MK., Franklin,R. and **Blalock,WL.** Effects of deregulated Raf and MEK1 expression on the cytokine-dependency of hematopoietic cells. (2000). *Adv. Enzyme Regul.* **40**: 305-337.
- Hoyle,PE., Moye,PW., Steelman,LS., **Blalock,WL.**, Franklin,RA., Pearce,M., Cherwinski,H., McMahan,M. and McCubrey,JA. Differential abilities of the Raf family of protein kinases to abrogate cytokine-dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. (2000). *Leukemia* **14**: 642-656.
- McCubrey,JA., Steelman,LS., Hoyle,PE., **Blalock,WL.**, Weinstein-Oppenheimer,C., Franklin,RA., Cherwinski,H., Bosch,E. and McMahan,M. Differential abilities of activated Raf oncoproteins to abrogate the cytokine-dependency, induce autocrine growth factor synthesis and alter the differentiation capacity of human hematopoietic cells. (1998). *Leukemia* **12**: 1903-1929.
- Stelman,LS., Algate,PA., **Blalock,WL.**, Wang,X-Y., Prevost,KD., Hoyle,PE. and McCubrey,JA. Oncogenic effect of overexpression of the IL-3 receptor on hematopoietic cells. (1996). *Leukemia* **10**: 528-542.

Book chapters:

- Stelman,LS., **Blalock,WL.**, Wang,XY., Moye,PW., Lee,JT., Shelton,JG., Navolanic,PM., Davis,JM., Knapp,SL., Franklin,RA., White,MK. and McCubrey,JA. Elucidation of signal transduction pathways by retroviral infection of cells with modified oncogenes. (2003). In: Terrian D.M. (eds) *Cancer Cell Signaling. Methods in Molecular Biology™*, vol 218. Humana Press pp. 221-252.
- Stelman,LS., **Blalock,WL.**, Wang,XY., Moye,PW., Lee,JT., Shelton,JG., Navolanic,PM., Davis,JM., Knapp,SL., Franklin,RA., White,MK. and McCubrey,JA. Elucidation of signal transduction pathways by transfection of cells with modified oncogenes. (2003). In: Terrian D.M. (eds) *Cancer Cell Signaling. Methods in Molecular Biology™*, vol 218. Humana Press pp. 203-220.
- Stelman,LS., **Blalock,WL.**, Wang,XY., Moye,PW., Lee,JT., Shelton,JG., Navolanic,PM., Davis,JM., Knapp,SL., Franklin,RA., White,MK. and McCubrey,JA. Fibroblastic, hematopoietic and hormone responsive epithelial cell lines and culture conditions for the elucidation of signal transduction and drug resistance pathways by gene transfer. (2003). In: Terrian D.M. (eds)

Cancer Cell Signaling. Methods in Molecular Biology™, vol 218. Humana Press pp. 185-201.

McCubrey,JA., Wang,XY., Algate,PA., **Blalock,WL.** and Steelman,LS. Autocrine Transformation: Cytokine Model. (2001). In: Blagosklonny M. V. (eds) Cell Cycle Check Points and Cancer, Molecular Biology Intelligence, Unit 15. Landes Bioscience pp. 1-16.

McCubrey,JA., **Blalock,WL.**, Chang,F., Steelman,LS., Pohnert,SC., Navolanic,PM., Shelton,JG., Hoyle,PE., Moye,PW., Oberhaus,SM., White,MK., Lee,JT. and Franklin,RA. Signal Transduction Pathways: Cytokine Model. (2001). In: Blagosklonny M. V. (eds) Cell Cycle Check Points and Cancer, Molecular Biology Intelligence, Unit 15. Landes Bioscience pp. 17-51.

Published abstracts from meetings:

First or last author (presenter):

Blalock,W., Bavelloni,A., Piazzini,M., Focaccia,E., Tomaselli,S., Cesarini,V., Faenza,I., Cocco,L. and Gallo,A. (2018). AKT1 phosphorylation of the adenosine deaminases, ADAR1p110 and ADAR2, alters editase activity. 60th Annual Meeting of the Italian Cancer Society, Milan, Italy.

Focaccia,E., Piazzini,M., Greco,S., Orsini,A., Cocco,L., Faenza,I., Bavelloni,A. and **Blalock,W.** Overexpression of the dsRNA-dependent kinase PKR in osteosarcoma cell promotes attachment independent growth and migration but not invasion. (2018). 60th Annual Meeting of the Italian Cancer Society, Milan, Italy.

Blalock,WL., Piazzini,P., Raffini,M., Faenza, I. and Bavelloni,A. Functional proteomics as a means to define signal transduction events in cancer. (2014). 19th World Congress on Advances in Oncology and 17th International Symposium on Molecular Medicine, Athens, Greece. Pubblicato in *International Journal of Molecular Medicine* **34 (S1):** S34.

Blalock,W., Raffini,M., Piazzini,M., Faenza,I. and Bavelloni,A. The Double-stranded RNA adenosine deaminase, ADAR1, represents a novel substrate for AKT. (2014). 56th Annual Meeting of the Italian Cancer Society, Ferrara, Italy.

Blalock,WL., Bavelloni,A., Tagliavini,F., Grimaldi,C., Maraldi,N. and Cocco,L. Identification of a nuclear isoform of the double-stranded RNA dependent protein kinase PKR in acute leukemia cells. (2009). 4th Annual Conference, Italian Proteomics Association, Milan, Italy.

Blalock,WL., Bennett,RL., Abtahi,FM. and May,WS. IFN-gamma/TNF-alpha hypersensitivity in Fanconi's anemia group C null fibroblasts is enhanced by expression of the PKR activator, RAX/PACT. (2004). 33rd Annual Meeting, International Society of Experimental Hematology, New Orleans, LA. Pubblicato in *Experimental Hematology* **32(7):** 46.

Blalock,WL., Pearce,M., Chang,F., Burrows,C., Moye,P., Steelman,LS., Aziz,A., McMahon,M. and McCubrey,JA. Abrogation of cytokine-dependency by MEK1 involves the PI3 kinase-AKT pathway and is enhanced by BCL2 overexpression or aberrant AKT activation. (2000). 42nd Annual Meeting, American Society of Hematology, San Francisco, CA. Pubblicato in *Blood* **96(11):** 77A.

Blalock,WL., Steelman,LS., Chang,F., Pearce,M., Moye,PW., Mirza,AM., McMahon,M. and McCubrey,JA. Autocrine transformation of hematopoietic cells by a conditionally-active form of MEK1 involves AKT and is enhanced by BCL2 expression. (2000). 91st Annual Meeting, American Association for Cancer Research, San Francisco, CA. Pubblicato in *Proc. AACR* **41:** 637.

- Blalock,WL.**, Steelman,LS., Pearce,M., Moye,PW., Chang,F. and McCubrey,JA. Transformation of hematopoietic cells to cytokine independence by Δ MEK1 alone and in synergy with BCL-2. (1999). 41st Annual Meeting, American Society of Hematology, New Orleans, LA. Pubblicato in *Blood* **94 (10)**: 474A-475A.
- Blalock,WL.**, Steelman,LS., Weinstein-Oppenheimer,CR., Chang,F., Pearce,M., Moye,PW., McMahon,M. and McCubrey,JA. Transformation of hematopoietic cells to cytokine-independence by a conditionally-active form of MEK1. (1999). 90th Annual Meeting, American Association of Cancer Research, Philadelphia, PA. Pubblicato in *Proc. AACR*. **40**: 371-372.
- Blalock,W.**, Franklin,R., Steelman,L., Hoyle,P., Atherfold,P., Cherwinski,H., McMahon,M. and McCubrey,J. Abrogation of cytokine dependency and inhibition of apoptosis in hematopoietic cells expressing a conditionally active form of MEK1. (1998). 51st Annual Symposium on Fundamental Cancer Research, Houston, TX. Pubblicato in 51st Annual Symposium on Fundamental Cancer Research Program and Abstracts, p. 119.
- Blalock,W.**, Franklin,R., Steelman,L., Hoyle,P., McCarthy,S., Cherwinski,H., McMahon,M. and McCubrey,J. Abrogation of cytokine-dependency and prevention of apoptosis in hematopoietic cells by the MEK1 oncoprotein. (1998). 89th Annual Meeting, American Association for Cancer Research, New Orleans, LA. Pubblicato in *Proc. AACR*. **39**: 38.

Co-author:

- Bavelloni,A., Piazzini,M., Ramazzotti,G., Fiume,R., Blalock,W. and Faenza,I. PI3K α 'selective inhibitor alpelisib (BYL719), may be effective as anticancer agents in Rhabdomyosarcoma. (2017). 71st National Meeting, Italian Society of Anatomy and Histology, Taormina, Italy. Pubblicato in *Italian Journal of Anatomy and Embryology* **122**: 21.
- Piazzini,M., Bavelloni,A., **Blalock,W.** and Faenza,I. From interaction to function: Phospholipase C beta 1 protects cells from stress-induced apoptosis. (2014). 68th National Meeting, Italian Society of Anatomy and Histology, Ancona, Italy. Pubblicato in *Italian Journal of Anatomy and Embryology* **119**: 1.
- Piazzini,M., Bavelloni,A., **Blalock,W.**, Fiume,R., D'Angelo,A., Matteucci,A., Cocco,L. and Faenza,I. Nuclear phospholipase C β 1 interactome: a morphological and proteomic approach. (2012). 66th National Meeting, Italian Society of Anatomy and Histology, Pistoia, Italy. Pubblicato in *Italian Journal of Anatomy and Embryology* **117**: 145.
- Bavelloni,A., Faenza,I., Piazzini,M., **Blalock,W.**, D'Angelo,A., Tagliavini,F., Pinetti,D., Matteucci,S., Mariani,GA. and Cocco, L. Identification of nuclear substrates of AKT/PKB by functional proteomics: prohibitin 2 is a target of AKT phosphorylation in human promyelocytic leukemia cells. (2011). 65th National Meeting, Italian Society of Anatomy and Histology, Padova, Italy. Pubblicato in *Italian Journal of Anatomy and Embryology* **116**: 19.
- Faenza,I., Bavelloni,A., **Blalock,W.**, Piazzini,M., Matteucci,S. and Cocco, L. Ectopic expression of PLC β 1 corrects differentiation of DM1 and DM2 myoblasts by normalizing cyclin D3 levels. (2010). 64th National Meeting, Italian Society of Anatomy and Histology, Messina-Taormina, Italy. Pubblicato in *Italian Journal of Anatomy and Embryology* **115**: 63.
- McCubrey,JA., **Blalock,WL.**, Tazzari,PL. Cappellini,A., Iacobucci,I., Chiarini,F., Abrams,SL., Ottaviani,E., Martinelli,G., Tarfuri,A., Cocco,L., Martelli,AM. and Falà,F. The AKT Inhibitor, A443654, Induces Cell Cycle Arrest, Apoptosis and Synergizes with Chemotherapeutic Drugs

- in Multi-Drug Resistant T-Cell Acute Lymphoblastic Leukemia - A Novel Agent for Therapy of Drug Resistant ALL. (2007). 49th Annual Meeting, American Hematological Society, Atlanta, GA. Pubblicato in *Blood* **110(11)**: 3344.
- Bennett,RL., **Blalock,WL.**, Moyer,SA. and May,WS. RAX-dependent PKR activation is required for host anti-viral defense after vesicular stomatitis virus infection. (2006). 97th Annual Meeting, American Association of Cancer Research, Washington, D.C. Pubblicato in *Cancer Research* **66 (8S)**: 1044-1045.
- Abtahi,FM., **Blalock,WL.**, Bennett,RL. and May,WS. RAX, the cellular activator of PKR, is required for stress induced apoptosis and anti-viral defense of MEF cells. (2005). 96th Annual Meeting, American Association of Cancer Research, Anaheim, CA. Pubblicato in *Cancer Research* **65(9S)**: 194.
- Steelman,L., Shelton,J., **Blalock,W.**, Navolanic,P. and McCubrey,J. Requirement for the PI3K/AKT pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. (2003). 32th Annual Meeting of the International Society for Experimental Hematology, Paris, France. Pubblicato in *Experimental Hematology* **31(7)**: 127.
- Shelton,J., **Blalock,W.**, Steelman,L. and McCubrey,J. Ability of activated PI3K/AKT oncoproteins to synergize with MEK1 and abrogate cytokine-dependence of hematopoietic cells. (2003). 32th Annual Meeting of the International Society for Experimental Hematology, Paris, France. Pubblicato in *Experimental Hematology* **31 (7)**: 129.
- McCubrey,J., Shelton,JG., Lee, JT, **Blalock,WL.**, Chang,F., Knapp,SL. and Steelman,L. Synergy amongst IGF-IR/PI3K/AKT, Raf/MEK/ERK and Src pathways in controlling cytokine-dependence and sensitivity to signal transduction inhibitors. (2002). 44th Annual Meeting of the American Society of Hematological, Philadelphia, PA. Pubblicato in *Blood* **100(11)**: 724A.
- Ruvolo,PP., Gao,FQ., Deng,XM., **Blalock,W.** and May,WS. A role for PKR and the cellular PKR activator, RAX in the potentiation of ceramide-induced apoptosis in hematopoietic cells. (2002). 42nd Annual Meeting, American Society of Hematology, San Francisco, CA. Pubblicato in *Blood* **96(11)**: 80A.
- Navolanic,PM., McCubrey,JA., Saleh,OA., Pearce,ML., **Blalock,WL.**, Steelman,LS., Burrows,CJ., Franklin,RA., Doshi,PD. and McKearn,JP. Effects of a chimeric cytokine, progenipoyetin, on apoptosis and gene expression. (2000). 42nd Annual Meeting, American Society of Hematology, San Francisco, CA. Pubblicato in *Blood* **96(11)**: 83A.
- McCubrey,JA., Shelton,JG., Steelman,LS., Pearce,ML., **Blalock,WL.**, Cooke,HJ., Kissner,M. and Frankel,AE. Enhanced ability of DT-IL3 to induce apoptosis in oncogene transformed human hematopoietic cells. (2000). 42nd Annual Meeting, American Society of Hematology, San Francisco, CA. Pubblicato in *Blood* **96(11)**: 97A.
- McCubrey,JA., Pohnert,S., Lee,JT., **Blalock,WL.**, Steelman,LS., Shelton,JG., Pearce,M., Franklin,RA., Mirza,A. and McMahan,M. Synergistic effects of activated PI3K/AKT expression on transformation of hematopoietic cells induced by oncogenic RAF and MEK1. (2000). 42nd Annual Meeting, American Society of Hematology, San Francisco, CA. Pubblicato in *Blood* **96(11)**: 498A.
- McCubrey,JA., Saleh,OA., Navolanic,PM., Pearce,ML., **Blalock,WL.**, Steelman,LS., Burrows,CJ., Lee,JT., Franklin,RA., Doshi,PD. and McKearn,JP. Enhanced ability of daniplestim and MPO-1 to suppress apoptosis and stimulate cytokine-inducible gene expression. (2000). 42nd Annual Meeting, American Society of Hematology, San Francisco, CA. Pubblicato in *Blood* **96(11)**: 139B.

- Pohnert,S., Moyer,P., **Blalock,W.**, Steelman,L., Burrows,C., McMahon,M., Mirza,A. and McCubrey,J. Synergistic effects of Akt on abrogation of cytokine-dependency induced by Raf and MEK. (2000). 29th Annual Meeting of the International Society for Experimental Hematology, Tampa, FL. Pubblicato in *Experimental Hematology* **28(7)**: 38.
- McCubrey,JA., **Blalock,W.**, Pearce,M., Steelman,L., Moyer,P., Burrows,C., Saleh,O., Smith,W., Doshi,P. and McKearn,J. Enhanced ability of myelopoietins, dual receptor agonists for human IL-3 and g-csf receptors, and the IL-3 receptor agonist, daniplestim, to suppress apoptosis and stimulate cytokine-inducible gene expression. (2000). 29th Annual Meeting of the International Society for Experimental Hematology, Tampa, FL. Pubblicato in *Experimental Hematology* **28(7)**: 39.
- McKearn,JP., Doshi,PD., Smith,WG., McCubrey,J., **Blalock,WL.**, Pearce,M., Steelman,LS., Moyer,PW. and Burrows,C. Enhanced ability of myelopoietins, dual receptor agonists for IL-3 and G-CSF receptors, to suppress apoptosis and stimulate cytokine-inducible gene expression. (2000). 91st Annual Meeting, American Association for Cancer Research, San Francisco, CA. Pubblicato in *Proc. AACR* **41**: 406.
- Moyer,PW., **Blalock,WL.**, Steelman,LS., Burrows,C., Franklin,RA., Mirza,AM., McMahon,M. and McCubrey,JA. Synergistic effects of AKT on abrogation of cytokine-dependency induced by RAF. (2000). 91st Annual Meeting, American Association for Cancer Research, San Francisco, CA. Pubblicato in *Proc. AACR* **41**: 635.
- Stelman,LS., **Blalock,WL.**, Moyer,PW., Burrows,C., Franklin,RA. and McCubrey,JA. Synergistic effects of the BCL-X_L oncoprotein on the abrogation of cytokine-dependency induced by the RAF and MEK1 oncoproteins. (2000). 91st Annual Meeting, American Association for Cancer Research, San Francisco, CA. Pubblicato in *Proc. AACR* **41**: 635.
- McCubrey,J., **Blalock,WL.**, Pearce,M., Steelman,LS., Moyer,PW., McLeod,A., Doshi,PD. and McKearn,JP. Enhanced ability of chimeric cytokines to suppress apoptosis and stimulate cytokine inducible gene expression. (1999). 41st Annual Meeting, American Society of Hematology, New Orleans, LA. Pubblicato in *Blood* **94(10)**: 149B.
- Stelman,LS., **Blalock,WL.**, Moyer,P., Chang,F., Hoyle,PE., McNeil,J., Lowe,M., Weinstein-Oppenheimer,CR. and McCubrey,JA. Synergy between Raf and Bcl-2 in abrogating the cytokine-dependency and increasing drug resistance of hematopoietic cells. (1999). 90th Annual Meeting, American Association of Cancer Research, Philadelphia, PA. Pubblicato in *Proc. AACR*. **40**: 372.
- Chang,F., Pearce,M., Hoyle,PE., **Blalock,WL.**, Steelman,LS. and McCubrey,JA. Effects of Raf genes on cell cycle progression and p16^{ink41} expression in human hematopoietic cells. (1999). 90th Annual Meeting, American Association of Cancer Research, Philadelphia, PA. Pubblicato in *Proc. AACR*. **40**: 372.
- Chang,F., Hoyle,P., **Blalock,W.**, Pearce,M., McNeil,J., Steelman,L. and McCubrey,J. Effects of Raf genes on cell cycle progression and prevention of apoptosis in human hematopoietic cells. (1998). 40th Annual Meeting, American Society of Hematology, Miami, FL. Pubblicato in *Blood* **92(10)**: 200A.
- McCubrey,J., **Blalock,W.**, Moyer,P., Chang,F., Hoyle,P., Weinstein-Oppenheimer,C., McNeil,J. and Steelman,L. Synergy between Raf and Bcl-2 in abrogating the cytokine-dependency of hematopoietic cells. (1998). 40th Annual Meeting, American Society of Hematology, Miami, FL. Pubblicato in *Blood* **92(10)**: 200A.
- McCubrey,J., Steelman,L., Hoyle,P., **Blalock,W.**, Weinstein,C., Franklin,R., Cherwinski,H., Bosch,E. and McMahon,M. Differential abilities of activated Raf oncoproteins to abrogate cytokine-

- dependency, induce autocrine transformation, P21 expression and prevent apoptosis in human hematopoietic cells. (1998). 11th International Symposium Molecular Biology of Hematopoiesis, Bormio, Italy. Pubblicato in *Acta Haematologica* **100 S1**: 47.
- Steelman,LS., Hoyle,PE., **Blalock,WL.**, Weinstein-Oppenheimer,C., Franklin,RA., Cherwinski,H., Bosch,E., McMahan,M. and McCubrey,JA. Differential abilities of Δ Raf:ER oncoproteins to abrogate the cytokine-dependency, induce autocrine growth factor synthesis and alter the differentiation capacity of human hematopoietic cells. (1998). 89th Annual Meeting, American Association for Cancer Research, New Orleans, LA. Pubblicato in *Proc. AACR* **39**: 37-38.
- Hoyle,PE., Bosch,E., Franklin,R., Steelman,LS., **Blalock,W.**, Cherwinski,H., McMahan,M. and McCubrey,JA. Raf induced signaling in murine hematopoietic cells. (1998). 89th Annual Meeting, American Association for Cancer Research, New Orleans, LA. Pubblicato in *Proc. AACR* **39**: 38.
- McCubrey,JA., Hoyle,P., Steelman,L., **Blalock,W.**, Franklin,R., Weinstein-Oppenheimer,C., Atherfold,P., Bosch,E., Cherwinski,H. and McMahan, M. Specific abilities of the RAF and MEK kinases to transform and alter the differentiation capacity of hematopoietic cells. (1997). 7th International Conference on Differentiation Therapy, Versailles, France. Pubblicato in *Anticancer Research* **17**: 3961.
- McCubrey,J., Hoyle,P., Steelman,L., **Blalock,W.**, Franklin,R., Weinstein-Oppenheimer,C., Atherfold,P., Bosch,E., Cherwinski,H. and McMahan,M. Specific abilities of members of the RAF and MEK families of protein kinases to transform hematopoietic cells. (1997). 2nd World Congress on Advances in Oncology, Athens, Greece. Pubblicato in *International Journal of Oncology* **11**: 914.
- Steelman,L., Hoyle,P., Weinstein,C., **Blalock,W.**, Cherwinski,H., McMahan,M. and McCubrey,J. Transformation of human hematopoietic cells by activated Raf oncoproteins: abilities of A-Raf and Raf-1 to induce Mek-dependent autocrine growth factor synthesis and inhibit differentiation. (1996). 38th Annual Meeting, American Society of Hematology, Orlando, FL. Pubblicato in *Blood* **88(10)**: 779A.
- Hoyle,P., Bosch,E., Steelman,L., **Blalock,W.**, Weinstein,C., Cherwinski,H., McMahan,M. and McCubrey,J. Differential Abilities of the Raf Family of Protein Kinases to Transform Hematopoietic Cells. (1996). 38th Annual Meeting, American Society of Hematology, Orlando, FL. Pubblicato in *Blood* **88(10)**: 782A.
- Pederson,NE., Shaver,P., **Blalock,W.**, Mettenleiter,TC. and Homa,FL. Complementation analysis of pseudorabies virus and herpes simplex virus UL28-null mutants. (1995). 21st Herpes Workshop, DeKalb, IL. Pubblicato nel *21st Herpesvirus Workshop Program and Abstracts*. Number 238.
- Jones,JP., **Blalock,WL.** and Stone,HO. Inhibition of translation of the Newcastle Disease Virus P protein. (1995). American Society for Microbiology. Washington, DC. Pubblicato nella programma della the 95th ASM General Meeting. **582**:T-4.